Skip to main content

Table 3 Summary of baseline and change data for lung function and validated questionnaires

From: Bronchiectasis Information and Education: a randomised, controlled feasibility trial

  No. Control group (n = 29) No. Intervention group (n = 31)
Baseline mean (SD) Mean changea, baseline to 2 weeks (SD) Mean change, baseline to 12 weeks (SD) Baseline mean (SD) Mean change, baseline to 2 weeks (SD) Mean change, baseline to 12 weeks (SD)
EQ-5D-5Lb
 Index value 29 0.75 (0.24) 0.01 (0.17)  -0.5 (0.19) 31 0.70 (0.23) 0.06 (0.13) 2.11 (11.7)
 VAS 29 68.6 (18.5) −1.55 (13.0) 0.48 (16.2) 31 65.4 (18.0) 5.97 (12.0) −3.0 (16.7)
SGRQc
 Symptoms 29 57.6 (23.4)   0.25 (15.0) 30 65.9 (21.3)   −7.89 (25.7)
 Activity 27 56.3 (23.5)   –4.85 (13.4) 31 56.1 (28.3)   −4.79 (14.8)
 Impacts 29 33.6 (21.5)   0.02 (11.3) 31 32.9 (17.2)   −3.06 (13.0)
 Total 27 46.1 (19.9)   −1.53 (8.3) 30 44.9 (19.1)   −2.62 (9.46)
QOL-Bd
 Physical 29 48.1 (32.3) 2.30 (17.8) -3.85 (16.7) 30 51.6 (35.1) 3.11 (16.2) -4.94 (25.2)
 Role 29 63.5 (29.3) 0.23 (13.6) 1.32 (17.6) 30 64.9 (25.8) 5.33 (18.7) 2.22 (17.8)
 Vitality 29 44.1 (24.0) –1.53 (18.5) 0.38 (16.9) 30 43.7 (22.4) 4.44 (18.4) -0.74 (21.0)
 Emotion 29 84.0 (17) 1.05 (14.9) -2.1 (13.0) 30 85.0 (18.6) 4.44 (15.3) 2.22 (10.2)
QOL-B         
 Social 29 59.7 (31.2) -0.077 (22.1) 2.97 (14.7) 30 58.1 (22.8) 5.37 (17.2) 3.14 (19.0)
 Treatment burdene 21 71.2 (22.7) –1.06 (16.8) 0.53 (14.7) 22 71.7 (21.6) 2.02 (14.8) 1.01 (14.1)
 Health 29 45.0 (25.3) 1.25 (18.2) -0.10 (13.0) 30 44.0 (24.3) 7.04 (15.8) 3.06 (18.4)
 Respiration 28 60.6 (23.7) 3.97 (17.3) 3.6 (16.3) 30 54.3 (22.8) 9.7 (14.6) 6.3 (16.8)
HADSf
 A 29 5.69 (3.87) –0.14 (2.86) –0.31 (3.11) 31 5.87 (4.01) −1.32 (2.4) 0.44 (6.6)
 D 29 4.52 (3.61) 0.00 (2.38) 0.14 (1.76) 31 3.81 (2.33) −0.10 (1.7) 2.12 (13.2)
FISg
 Cognitive 29 8.52 (9.44)   2.07 (7.2) 31 7.55 (5.84)   1.26 (5.7)
 Physical 29 15.52 (12.3)   −1.69 (5.6) 31 12.9 (8.18)   0.39 (6.9)
 Social 29 21.79 (21.95)   −0.59 (8.8) 31 15.7 (13.4)   2.72 (12.9)
 Total 29 45.8 (42.5)   −0.21 (18.3) 31 36.2 (26.0)   2.70 (19.7)
FEV1 (% predicted) 28 72.6 (26.7)   3.78 (8.61) 30 63.7 (23.8)   −0.78 (10.1)
FEV1 (L) 28 1.82 (0.73)   0.08 (0.23) 30 1.64 (0.75)   0.23 (1.15)
  1. Abbreviations: EQ-5D-5L 5-level EuroQol 5-dimension quality of life scale, FEV1 forced expiratory volume in 1 s, FIS Fatigue Impact Scale, HADS Hospital Anxiety and Depression Scale, QOL-B Quality of Life–Bronchiectasis, SGRQ St George’s Respiratory Questionnaire, VAS visual analogue scale
  2. aA negative change indicates a numerical fall, on average, from baseline to 12 weeks
  3. bEuroQol-5D-5L: self-reported health status (VAS range, 0–100%)
  4. cSt George’s Respiratory Questionnaire: scores are a percentage of overall impairment; 100 represents worst possible health status, and 0 indicates best possible health status
  5. dQuality of Life – Bronchiectasis: scored 0–100, higher score = better quality of life
  6. eTreatment burden is not scored if participant is receiving no treatment, hence apparent lower n value
  7. fHospital Anxiety and Depression Scale: anxiety 0–21, depression 0–21; scores 11+ are significant
  8. gFatigue Impact Scale: cognitive, 0–40; physical, 0–40; social, 0–80; total, 0–160. Higher score = bigger impact of fatigue